Overview

Theraclion is the leading specialist in the non-invasive treatment of fine targets using High-Intensity Focused Ultrasound (HIFU) guided by real-time echography.

Based in Paris, France, within the Cochin University Hospital, Theraclion is supported by an international medical and scientific committee composed of surgeons, radiologists, endocrinologists, nephrologists and physicists.

Our goal is to bring innovative breakthrough technologies to the world of healthcare. Theraclion’s solution offers a unique, simple, non-invasive, cost-efficient solution for surgeons to treat pathologies such as thyroid nodules and hyperparathyroidism.

Theraclion's main shareholder is Truffle Capital, a leading Venture Capital firm in Europe.
The company is also supported by the French Government through its Innovation and Development Fund, OSEO.